“Superficial venous treatments have come a long way in the last 20 years,” Manj Gohel (Cambridge, UK) tells Venous News, before outlining the key aims of the VenaSeal Spectrum programme—which includes three studies (two randomised and one prospective observational study)—which will compare the VenaSeal closure system against surgical stripping or endothermal ablation (ETA) for the treatment of early and advanced stage superficial venous disease. The 30-day primary endpoint results of VenaSeal Spectrum will be presented this year at the 45th Charing Cross International Symposium (25–27 April, London, UK, in person and virtual) during the Superficial Venous and Lymphatic session on Day 2.
In this video, Gohel also highlights how “we have a tremendous variety of treatments available to us and for thermal treatment we have a very robust evidence base.” However, for the new non-thermal treatments, “it is fair to say that the evidence level isn’t quite the same for these and we really need to address that”, he says. Manufacturers “need to work hard” to provide safety and efficacy data adds Gohel, who notes that “ideally, we want randomised clinical trials comparing new treatments with current established gold standards. Only then will we know if these treatments have a significant role to play in treating our patients”.
